A pilot study of preoperative ipilimumab (anti-CTLA-4) and cryoablation in 19 women with early-stage breast cancer was conducted to determine the safety and tolerability of monotherapy and combinational therapy (23) (Table 1). This evidence concerns the gene CTLA4 and breast carcinoma.